Ilya Yuffa, head of international for US weight-loss drugmaker Eli Lilly, wants Australia to shrink the approval time for new medicines. Dominic Lorrimer Ilya Yuffa, who heads Eli Lilly’s ...

Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and media ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

We recently published a list of Jim Cramer Says Trump’s Fed Chair Tussle Is Like “The Godfather” & Discusses These 10 Stocks. In this article, we are going to take a look at where Eli Lilly ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

April 25, 2025 Lilly requests EMA to re-examine Alzheimer's drug recommendation Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...